thumbnail image
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
    • LungCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
      • LungCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
broken image
broken image

seek and you will find

  • Home
  • Technology
  • Products 
    • Products Overview
    • SeekInCare
    • SeekInCure
    • SeekInClarity
    • OncoSeek
    • LeukoPrint
    • PanCanSeek
    • LungCanSeek
  • Publication 
    • Research
    • Others
  • Newsroom
  • Product & Service Inquiry
  • …  
    • Home
    • Technology
    • Products 
      • Products Overview
      • SeekInCare
      • SeekInCure
      • SeekInClarity
      • OncoSeek
      • LeukoPrint
      • PanCanSeek
      • LungCanSeek
    • Publication 
      • Research
      • Others
    • Newsroom
    • Product & Service Inquiry
broken image
  • SeekInClarity®

    Pan-cancer, pan-indication treatment response monitoring

    broken image

    Therapeutic efficacy monitoring is essential in cancer care, assessing tumor burden changes, treatment response, early drug resistance, and long-term efficacy. This enables personalized precision medicine to enhance outcomes and patient quality of life.

    SeekInClarity® is a non-invasive, pan-cancer, pan-indication solution for advanced cancer patients. By detecting molecular signals earlier than traditional methods, it supports timely clinical decisions to improve patient outcomes.

    Pan-cancer

    Pan-indication

    Early assessment

    Progression prediction

  • Highlights

    • Circulating tumor DNA (ctDNA) and proteins were analyzed from a single blood draw using a multiomics approach.
    • Equipped with proprietary artificial intelligence (AI) and big data-driven molecular tumor burden (MTB) algorithms, it generates MTB scores that reflect cancer signals.

    broken image
  • Testing time

    broken image

    Before treatment,

    use to set a personalized baseline level.

    After treatment,

    compare with the baseline to check if the treatment is working well.

    Early progression detection,

    surveillance with greater sensitivity to detect cancer progression earlier than current standard of care tools.

  • Specifications

    ◉ Indicated subjects: patients who are diagnosed with advanced cancer

    ◉ Sample requirement: 8ml peripheral blood

    ◉ Result readout: molecular tumor burden (MTB)

    ◉ Turnaround time (TAT): 10 working days

    broken image

    By showing the increase or decrease in MTB between two tests, it reflects changes in cancer signals and highlights the effectiveness of treatment.

  • How it works

    broken image

    Customer order

    Customers can place orders through SeekIn official website or local agents

    broken image

    Blood-draw

    8 ml venous peripheral blood collected in cell-free DNA streck tube and can be stably stored at room temperature for 5 days

    broken image

    Testing

    Detection by Roche cobas e411 instrument + next generation sequencing (NGS) platform

    broken image

    Reporting

    The test results will be ready in about 10 workdays after your blood draw arrived at central lab

  • Please review the instructions to gain a better understanding of SeekInClarity® and assess whether it meets your needs.

    Download the Instructions

Navigation

Technology   

SeekInCare

SeeInCure

SeekInClarity

OncoSeek

Research

Contact Us

10320 Camino Santa Fe, Suite G

San Diego, CA 92121

United States

info@seekincancer.com

© 2024 SeekIn Inc.

All Rights Reserved.

Cookie Use
We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
Learn More